By Fineline Cube CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that its CAR-T therapy Kylimei (satricabtagene autoleucel injection) has received approval from China’s National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have failed at least two prior lines of therapy.
Regulatory Milestone Details
| Parameter | Detail |
|---|---|
| Company | CARsgen Therapeutics Holdings Limited (HKG: 2171) |
| Product | Kylimei (satricabtagene autoleucel injection) |
| Approval Authority | National Medical Products Administration (NMPA), China |
| Approval Date | June 22, 2026 |
| Indication | Claudin18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma (≥2 prior therapies) |
| Patient Population | Heavily pre-treated patients with limited therapeutic options |
| Global Significance | World’s first CAR-T cell therapy approved for solid tumors |
Product Profile & Innovation
- Classification: First-in-class (FIC) autologous humanized CAR-T cell therapy
- Target: Claudin18.2, a tumor-specific antigen highly expressed in gastric and GEJ cancers
- Therapeutic Breakthrough: Represents the first successful application of CAR-T technology to solid tumors globally
- Manufacturing: Autologous process involving patient leukapheresis, genetic modification, and reinfusion
Clinical Development Expansion Strategy
CARsgen is actively advancing Kylimei into earlier-stage disease settings through multiple clinical programs:
- Adjuvant Pancreatic Cancer: Phase I trial in China (NCT05911217)
- Post-Surgical Consolidation: Investigator-initiated trial (IIT) for gastric/GEJ adenocarcinoma after radical resection (NCT06857786)
- Sequential Therapy: IIT following first-line treatment of gastric/GEJ adenocarcinoma (NCT07179484)
Strategic Market Implications
- Solid Tumor Barrier Broken: Overcomes historical challenges of CAR-T efficacy in solid tumors, including tumor microenvironment suppression and target antigen heterogeneity
- Addressable Population: Targets a significant unmet need in gastric cancer, which represents one of the most common malignancies in Asia
- Competitive Landscape: Establishes CARsgen as the pioneer in solid tumor CAR-T therapy with substantial first-mover advantage
- Global Potential: NMPA approval provides foundation for international regulatory submissions and potential global expansion
Commercial Outlook
The approval positions Kylimei as a premium-priced therapy for end-stage gastric cancer patients, with potential annual pricing in the range of USD 300,000–500,000 based on comparable CAR-T products. CARsgen’s manufacturing infrastructure in China supports commercial-scale production, while the ongoing earlier-stage trials could significantly expand the addressable market if successful.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ materially due to risks including manufacturing scalability, market adoption, competitive dynamics, and clinical trial outcomes in earlier-stage settings.-Fineline Info & Tech